Abstract:
Objective To study the relation between donor-recipient human leukocyte antigen (HLA) mismatching and combined malignant tumors after renal transplantation.
Methods Clinical data of 1 021 patients who received renal transplantation from 1993 to 2009 in Department of Urology of Beijing Friendship Hospital of Affiliated Capital University of Medical Sciences over 5 years and had complete HLA typing were analyzed. In the 1 021 patients after renal transplantation, 928 cases were non-tumor patients and 93 cases were malignant tumor patients. The mismatching data of 3 locus (HLA-A, B and DR) with a total of 6 antigens of the donors and recipients were collected. The relation between donor-recipient HLA mismatching number and postoperative combined malignant tumors was analyzed. And that between genders was also analyzed.
Results Malignant tumors occurred in 9.11%(93/1 021)of the patients. The malignant tumor incidences of patients with HLA mismatch of 0-1, 2, 3, 4, 5 and 6 antigens were 14%, 13%, 14%, 6%, 3% and 4% respectively. Patients with HLA over half-matched (0-3 antigens mismatch) had higher incidence of malignant tumors compared with that in patients with HLA less than half matched (4-6 antigens mismatch) (14% vs. 5%;χ2=24.11,P<0.005). In the malignant tumor patients of 0-3 antigens mismatch, 12 cases were males and 54 cases were females. In the patients of 4-6 antigens mismatch, 12 cases were males and 15 cases were females. The proportion of female patients of 0-3 antigens mismatch was higher than that of male patients(χ2=5.60,P<0.025).
Conclusions For the renal transplant patients, especially female patients, the lower the HLA mismatching number is, the higher the malignant tumor incidence is.